Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

NCT06830759 · tracked via the Priya Life Science Mexico tracker

Sponsor

AbbVie

Phase

Observational

Started

2025-03-28

Last updated

2026-02-17

Condition(s) studied

Diffuse Large B-cell LymphomaFollicular Lymphoma

Study summary

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the real-world effectiveness of subcutaneous epcoritamab in adult participants with advanced DLBCL and FL.

Epcoritamab is an investigational drug being developed for treating participants with DLBCL and FL. Approximately 700 participants will be enrolled in approximately 80 sites across 12-20 countries globally.

Participants will receive epcoritamab as prescribed by their physician in accordance with local country label. Participants will be followed for up to 3 years.

There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Participants who are scheduled to be treated with epcoritamab for Treatment after two or more prior lines of therapy 3L+ diffuse large B-cell lymphoma ((D)LBCL) or 3L+ Follicular lymphoma (FL). * Treatment with epcoritamab should be administered in accordance with the approved local label in the participating country. * The decision to treat the participant should have been made by the clinician prior to, and independently of any decision to approach the participant to participate in this study. Exclusion Criteria: * Any condition included in the contraindications section of the approved local epcoritamab label in the participating country. * Participation in a concurrent interventional clinical trial (not including non-interventional/ observational study, PMOS, or registry participation) from enrollment and throughout the study.

Primary outcome measure(s)

Percentage of Participants Achieving Overall Response (OR) — Up to approximately 3 years
Defined as the percentage of participants who achieve best overall response of complete response (CR) or partial response (PR) determined by Lugano criteria

Trial sites (73)

Facility	City	Region	Status
Hospital Britanico de Buenos Aires /ID# 274419	Ciudad Autonoma de Buenos Aire	Buenos Aires	Recruiting
Hospital Universitario Austral /ID# 274393	Pilar	Buenos Aires	Recruiting
Instituto Alexander Fleming /ID# 277284	Ciudad Autonoma de Buenos Aire	Buenos Aires F.D.	Recruiting
Hospital Privado Universitario De Córdoba /ID# 274457	Córdoba	Córdoba Province	Recruiting
Hospital Italiano de Buenos Aires /ID# 274418	Buenos Aires	Argentina	Recruiting
Fundacion Argentina contra la Leucemia (FUNDALEU) /ID# 274390	Buenos Aires	Argentina	Recruiting
Nepean Cancer Centre, Nepean Hospital /ID# 277782	Kingswood	New South Wales	Recruiting
Calvary Mater Newcastle /ID# 277783	Waratah	New South Wales	Recruiting
Cabrini Hospital Malvern /ID# 277780	Malvern	Victoria	Recruiting
Krankenhaus Der Barmherzigen Brueder Graz /ID# 273288	Graz	Styria	Recruiting
Landeskrankenhaus Hochsteiermark, Standort Leoben /ID# 273266	Leoben	Styria	Recruiting
Algemeen Ziekenhuis klina /ID# 273405	Brasschaat	Antwerpen	Recruiting
Universitair Ziekenhuis Brussel /ID# 273403	Jette	Brussels Capital	Recruiting
Centre Hospitalier Epicura - Hornu /ID# 273406	Boussu	Hainaut	Recruiting
Grand Hôpital De Charleroi - Notre Dame /ID# 273728	Charleroi	Hainaut	Recruiting
Helora /ID# 273726	La Louvière	Hainaut	Recruiting
Groupe Sante CHC - Clinique du MontLegia /ID# 273407	Liège	Liege	Recruiting
Ziekenhuis Oost-Limburg, Campus St.-Jan /ID# 273729	Genk	Limburg	Recruiting
Vitaz /Id# 273408	Sint-Niklaas	Oost-Vlaanderen	Recruiting
AZ Oostende /ID# 273714	Ostend	West-Vlaanderen	Recruiting
Umhat Sveti Ivan Rilsky /ID# 274898	Sofiya	Sofia	Recruiting
University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski /ID# 274893	Pleven	Bulgaria	Recruiting
Acibadem City Clinic Tokuda University Hospital EAD /ID# 273659	Sofia	Bulgaria	Recruiting
Specialized Hospital For Active Treatment Of Haematology Diseases /ID# 274955	Sofia	Bulgaria	Recruiting
Cross Cancer Institute /ID# 271504	Edmonton	Alberta	Recruiting
The Moncton Hospital /ID# 277230	Moncton	New Brunswick	Recruiting
Eastern Health - General Hospital /ID# 272062	St. John's	Newfoundland and Labrador	Recruiting
Health Sciences North /ID# 274738	Greater Sudbury	Ontario	Recruiting
Kingston General Hospital /ID# 272061	Kingston	Ontario	Recruiting
Agios Andreas Hospital Patras /ID# 273629	Pátrai	Achaia	Recruiting
Evangelismos Hospital /ID# 272736	Athens	Attica	Recruiting
General Hospital of Athens Laiko /ID# 272758	Athens	Attica	Recruiting
University General Hospital Attikon /ID# 272738	Athens	Attica	Recruiting
Metaxa Cancer Hospital Of Piraeus /ID# 273623	Piraeus	Attica	Recruiting
University General Hospital of Alexandroupoli /ID# 272737	Alexandroupoli	Evros	Recruiting
University Hospital of Ioannina /ID# 272739	Ioannina	Greece	Recruiting
AHEPA University General Hospital of Thessaloniki /ID# 273633	Thessaloniki	Greece	Recruiting
General Hospital of Thessaloniki Hippokrateio /ID# 273635	Thessaloniki	Greece	Recruiting
Papageorgiou General Hospital /ID# 272735	Thessaloniki	Greece	Recruiting
General Hospital Of Thessaloniki G. Papanikolaou /ID# 275323	Thessaloniki	Greece	Recruiting

+ 33 more sites — see the full list on the official registry below.

More AbbVie trials in Mexico

A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis Active, not recruiting

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate Active, not recruiting

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer Active, not recruiting

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy Active, not recruiting

Other trials for the same condition

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas Active, not recruiting

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. Active, not recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) Recruiting

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Recruiting

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06830759 on ClinicalTrials.gov ↗ ← All trials in Mexico